Changing Treatment Paradigms for Brain Metastases From Melanoma-Part 2: When and How to Use the New Systemic Agents.

Vyshak Alva Venur; Pauline Funchain; Rupesh Kotecha; Samuel T Chao; Manmeet S Ahluwalia

Changing Treatment Paradigms for Brain Metastases From Melanoma-Part 2: When and How to Use the New Systemic Agents.

Vyshak Alva Venur
, Pauline Funchain
, Rupesh Kotecha
, Samuel T Chao
, Manmeet S Ahluwalia

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Oncology
Volume	31
State	Published - Sep 15 2017

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Cite this

@article{854858b0ec0b4c46a7b69e67d3da5415,

title = "Changing Treatment Paradigms for Brain Metastases From Melanoma-Part 2: When and How to Use the New Systemic Agents.",

author = "Venur, \{Vyshak Alva\} and Pauline Funchain and Rupesh Kotecha and Chao, \{Samuel T\} and Ahluwalia, \{Manmeet S\}",

note = "Until recently, therapeutic strategies for melanoma brain metastases focused on local treatments: surgery, whole-brain radiation therapy, and stereotactic radiosurgery. Historically, systemic therapy had limited utility. Immunotherapeutic drugs, such as anti-cytotoxic T-lymphocyte-associated antigen 4 and anti-programmed death 1 agents, and agents targeting the BRAF-MEK pathway have revolutionized the systemic treatment of melanoma brain metastases.",

year = "2017",

month = sep,

day = "15",

language = "American English",

volume = "31",

journal = "Oncology",

}

TY - JOUR

T1 - Changing Treatment Paradigms for Brain Metastases From Melanoma-Part 2: When and How to Use the New Systemic Agents.

AU - Venur, Vyshak Alva

AU - Funchain, Pauline

AU - Kotecha, Rupesh

AU - Chao, Samuel T

AU - Ahluwalia, Manmeet S

N1 - Until recently, therapeutic strategies for melanoma brain metastases focused on local treatments: surgery, whole-brain radiation therapy, and stereotactic radiosurgery. Historically, systemic therapy had limited utility. Immunotherapeutic drugs, such as anti-cytotoxic T-lymphocyte-associated antigen 4 and anti-programmed death 1 agents, and agents targeting the BRAF-MEK pathway have revolutionized the systemic treatment of melanoma brain metastases.

PY - 2017/9/15

Y1 - 2017/9/15

UR - https://pubmed.ncbi.nlm.nih.gov/29071693/

M3 - Article

VL - 31

JO - Oncology

JF - Oncology

ER -

Changing Treatment Paradigms for Brain Metastases From Melanoma-Part 2: When and How to Use the New Systemic Agents.

Disciplines

Other files and links

Cite this